Abstract
This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal pathology as measured by plasma surrogate markers. In this 1-year observational study 30 multiple sclerosis (MS) patients with relapsing-remitting disease were treated with intramuscular IFNbeta-1a or subcutaneous IFNbeta-1b. Responders and nonresponders were defined according to clinical and magnetic resonance imaging criteria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate markers for inflammation (nitric oxide metabolites (NOx)), astrocytic activation (S100B) and axonal damage (NfH(SM135)) were measured using standard assays. There were 11 nonresponders and 19 responders to IFNbeta treatment. Median S100B levels were elevated in a higher proportion of treatment responders (63%, 42.9 pg/mL) compared to nonresponders (18%, 11.7 pg/mL, P < 0.05, Fisher's exact test) and controls (0%, 2 pg/mL, P < 0.001). Levels of NOx were found to be more frequently elevated in nonresponders (72%, 39 microM) compared to healthy controls (0%, 37 microM, P < 0.05). Levels of NfH(SM135) were more frequently elevated in responders (58%, 300 pg/mL, P < 0.001) and nonresponders (72%, 500 pg/mL, P < 0.001) c...Continue Reading
References
Jul 16, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·G KeirE J Thompson
Apr 1, 1996·Neurology·F D Lublin, S C Reingold
Jul 1, 1996·Brain Pathology·C F LucchinettiH Lassmann
Jan 1, 1997·Journal of the Neurological Sciences·G GiovannoniE J Thompson
Jun 23, 1997·Journal of Immunological Methods·A J GreenE J Thompson
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Feb 17, 2001·Nitric Oxide : Biology and Chemistry·K M MirandaD A Wink
Jun 8, 2001·The International Journal of Biochemistry & Cell Biology·R Donato
Aug 8, 2001·Trends in Neurosciences·P Rieckmann, K J Smith
Sep 18, 2001·Annals of Neurology·K P WandingerR Martin
May 25, 2002·CNS Drugs·Andreas Bitsch, Wolfgang Brück
Jun 22, 2002·Brain : a Journal of Neurology·A PetzoldG Giovannoni
Sep 6, 2003·Journal of Immunological Methods·A PetzoldE J Thompson
Citations
May 10, 2007·Clinical and Experimental Immunology·A AchironM Mandel
Oct 2, 2009·Nature Reviews. Neurology·Jordi RíoXavier Montalban
Nov 19, 2011·Multiple Sclerosis International·Barbara TavazziGiuseppe Lazzarino
Nov 19, 2011·Multiple Sclerosis International·Irena Dujmovic
Nov 19, 2011·Multiple Sclerosis International·M J EikelenboomA Petzold
Mar 13, 2012·The FEBS Journal·Aye M Myint
Sep 28, 2013·PloS One·Johanna GaiottinoJens Kuhle
May 17, 2008·CNS Neuroscience & Therapeutics·Jop P MostertJacques De Keyser
Nov 19, 2011·Multiple Sclerosis International·Melissa M GresleGerry Shaw
Nov 22, 2012·Clinical and Experimental Pharmacology & Physiology·Ryusuke TakechiJohn C Mamo
Dec 17, 2015·Journal of Neuroinflammation·L SchreweA Chan
May 30, 2019·Annals of Clinical and Translational Neurology·Basil T DarrasCharlotte J Sumner
Jan 27, 2006·Annals of Neurology·Jordi RíoXavier Montalban
Oct 10, 2012·The Pharmacogenomics Journal·V Foti CuzzolaS Marino
Oct 19, 2007·Multiple Sclerosis : Clinical and Laboratory Research·Elke WiesemannAnja Windhagen
Aug 13, 2013·PloS One·Sharmilee GnanapavanGavin Giovannoni
Mar 6, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Gavin Giovannoni
Jul 6, 2010·Acta Neurologica Scandinavica·H Bartosik-PsujekZ Stelmasiak
Mar 30, 2011·FEBS Letters·Djordje MiljkovićMarija Mostarica Stojković
Nov 14, 2008·Expert Opinion on Pharmacotherapy·Iván Martinez-ForeroPablo Villoslada
Nov 9, 2016·Molecular Neurobiology·Giacomo LazzarinoBarbara Tavazzi
Aug 25, 2012·Multiple Sclerosis : Clinical and Laboratory Research·M KhalilC E Teunissen
Mar 1, 2012·BMB Reports·Jung Hoon Kang
Jul 31, 2018·Brain : a Journal of Neurology·Gavin Giovannoni
Feb 2, 2010·Journal of Neuroimmunology·Jens KuhleAxel Petzold
May 18, 2005·Journal of the Neurological Sciences·Axel Petzold
Jun 29, 2007·Journal of Translational Medicine·Thomas E IchimNeil H Riordan